Eleutheroside E Ameliorates Arthritis Severity in Collagen-Induced Arthritis Mice Model by Suppressing Inflammatory Cytokine Release

被引:0
作者
Chunyan He
Xiaohui Chen
Chunyang Zhao
Yanyan Qie
Zhaowei Yan
Xueming Zhu
机构
[1] The Second Affiliated Hospital of Soochow University,Department of Clinical Laboratory
[2] The Second Affiliated Hospital of Soochow University,Department of Radiology
[3] The First Affiliated Hospital of Soochow University,Department of Clinical Pharmacology
来源
Inflammation | 2014年 / 37卷
关键词
eleutheroside E; rheumatoid arthritis; inflammatory cytokines; treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Rheumatoid arthritis is the most common arthritis and is mainly characterized by symmetric polyarticular joint disorders. Eleutheroside E (EE), a principal active constituent of Acanthopanax senticosus, is reported to have anti-inflammatory effect by inhibiting NF-κB activities. However, the effects of EE on rheumatoid arthritis (RA) severity are largely unknown. The purpose of this study was to indicate whether EE could ameliorate arthritis and reduce inflammatory cytokine release in collagen-induced arthritis (CIA) mice. The results showed that EE attenuated the severity of arthritis by reducing the mean arthritis score and arthritis incidence. EE also significantly decreased the inflammatory cell infiltration, pannus formation, cartilage damage, and bone erosion of CIA mice. Furthermore, EE caused a marked decrease of the production of TNF-α and IL-6 in vivo and in vitro. These observations identify a novel function of EE that results in inhibition of cytokine release, highlighting EE was a potential therapeutic agent for RA.
引用
收藏
页码:1533 / 1543
页数:10
相关论文
共 158 条
  • [1] Weissmann G(2006)The pathogenesis of rheumatoid arthritis Bulletin of the NYU Hospital for Joint Diseases 6 12-15
  • [2] Feldmann M(2008)Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics Immunological Reviews 223 7-19
  • [3] Maini SR(1993)Interleukin-6 in synovial-fluid is closely associated with chronic synovitis in rheumatoid arthritis Rheumatology International 13 45-51
  • [4] Sack U(1993)Serum interleukin-6 levels in rheumatoid arthritis-correlations with clinical and laboratory indexes of disease activity Annals Rheumatic Diseases 52 232-234
  • [5] Kinne RW(2011)The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis Arthritis 169 3353-3362
  • [6] Marx T(2002)IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae Journal of Immunology 78 79-87
  • [7] Heppt P(1998)Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage Laboratory Investigation 19 163-196
  • [8] Bender S(2001)Anti-TNFα therapy or rheumatoid arthritis: what have we learned? Annual Review Immunology 66 1132-1136
  • [9] Emmrich F(2007)What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortalityin rheumatoid arthritis? A review of the role of TNF alpha in cardiovascular pathophysiology Annals of the Rheumatic Disease 48 2122-2127
  • [10] Madhok R(2003)Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis and Rheumatism 43 2383-2390